Based on current studies, PTEN is an emerging biomarker for recurrent HNSCC and using treatments that target the hyperactive downstream pathway (PI3K/AKT/mTOR) in combination with first-line therapies may prove to be uniquely effective in HNSCC patients with decreased PTEN expression. The gene discussed is PTEN; the disease is head and neck squamous cell carcinoma.